Ifinatamab deruxtecan: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
'''Ifinatamab | {{DISPLAYTITLE:Ifinatamab deruxtecan}} | ||
== Ifinatamab Deruxtecan == | |||
[[File:Deruxtecan_ADCs.svg|thumb|right|Diagram of Antibody-Drug Conjugates (ADCs) including Deruxtecan]] | |||
'''Ifinatamab deruxtecan''' is a novel [[antibody-drug conjugate]] (ADC) designed for the targeted treatment of certain types of [[cancer]]. It combines a monoclonal antibody specific to a tumor-associated antigen with a potent cytotoxic agent, [[deruxtecan]], which is a derivative of the chemotherapy drug [[exatecan]]. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Ifinatamab | Ifinatamab deruxtecan works by specifically targeting cancer cells that express a particular antigen. The monoclonal antibody component of the ADC binds to the antigen on the surface of the cancer cell. Once bound, the entire ADC is internalized into the cell, where the cytotoxic agent, deruxtecan, is released. This release occurs through the cleavage of a linker that connects the antibody to the drug. The released deruxtecan then exerts its cytotoxic effects by inhibiting [[topoisomerase I]], leading to [[DNA damage]] and ultimately cell death. | ||
== Clinical Trials == | == Development and Clinical Trials == | ||
Ifinatamab deruxtecan is currently under investigation in various [[clinical trials]] to evaluate its efficacy and safety in treating different types of cancer, including [[breast cancer]], [[lung cancer]], and [[gastric cancer]]. These trials aim to determine the optimal dosing, therapeutic efficacy, and potential side effects of the drug. | |||
== Side Effects == | == Potential Side Effects == | ||
As with | As with other ADCs, ifinatamab deruxtecan may cause a range of side effects. Common side effects include [[nausea]], [[fatigue]], and [[myelosuppression]]. More serious side effects can include [[interstitial lung disease]] and severe [[neutropenia]]. Monitoring and management of these side effects are crucial during treatment. | ||
== Future Directions == | == Future Directions == | ||
Research is ongoing to explore the full potential of ifinatamab deruxtecan in combination with other therapies, such as [[immunotherapy]] and [[radiotherapy]]. Additionally, efforts are being made to identify biomarkers that can predict response to treatment, which would allow for more personalized therapy approaches. | |||
== Related Pages == | |||
* [[Antibody-drug conjugate]] | |||
* [[Monoclonal antibody therapy]] | |||
* [[Cancer treatment]] | |||
* [[Topoisomerase inhibitor]] | |||
[[Category:Antibody-drug conjugates]] | [[Category:Antibody-drug conjugates]] | ||
[[Category:Cancer treatments]] | |||
Latest revision as of 11:33, 15 February 2025
Ifinatamab Deruxtecan[edit]
Ifinatamab deruxtecan is a novel antibody-drug conjugate (ADC) designed for the targeted treatment of certain types of cancer. It combines a monoclonal antibody specific to a tumor-associated antigen with a potent cytotoxic agent, deruxtecan, which is a derivative of the chemotherapy drug exatecan.
Mechanism of Action[edit]
Ifinatamab deruxtecan works by specifically targeting cancer cells that express a particular antigen. The monoclonal antibody component of the ADC binds to the antigen on the surface of the cancer cell. Once bound, the entire ADC is internalized into the cell, where the cytotoxic agent, deruxtecan, is released. This release occurs through the cleavage of a linker that connects the antibody to the drug. The released deruxtecan then exerts its cytotoxic effects by inhibiting topoisomerase I, leading to DNA damage and ultimately cell death.
Development and Clinical Trials[edit]
Ifinatamab deruxtecan is currently under investigation in various clinical trials to evaluate its efficacy and safety in treating different types of cancer, including breast cancer, lung cancer, and gastric cancer. These trials aim to determine the optimal dosing, therapeutic efficacy, and potential side effects of the drug.
Potential Side Effects[edit]
As with other ADCs, ifinatamab deruxtecan may cause a range of side effects. Common side effects include nausea, fatigue, and myelosuppression. More serious side effects can include interstitial lung disease and severe neutropenia. Monitoring and management of these side effects are crucial during treatment.
Future Directions[edit]
Research is ongoing to explore the full potential of ifinatamab deruxtecan in combination with other therapies, such as immunotherapy and radiotherapy. Additionally, efforts are being made to identify biomarkers that can predict response to treatment, which would allow for more personalized therapy approaches.
